Millennium Pharmacon International Tbk PT

Millennium Pharmacon International Tbk maintains a debt-to-equity ratio of 2.57, indicating a capital structure that is significantly leveraged. The company's liquidity position is characterized by a current ratio of 1.1, suggesting limited short-term liquidity cushion. Free cash flow stands at 10.2 billion IDR, but this is dwarfed by the 809.8 billion IDR in long-term debt. Profitability metrics show a return on equity of 12.2%, which is strong relative to the typical pharmaceutical industry benchmark of 10-15%. However, the return on assets of 1.96% is below the industry median of 3-5%, indicating underutilization of asset base. Operating margin of 27.6% (calculated from operating income of 113.5 billion IDR on 410.98 billion IDR revenue) is in line with industry norms. The company's revenue is concentrated across three segments: Prescription Medicine, Medical Devices, and Non-prescription Medicine. No segment-specific revenue figures are disclosed, but the distribution network spans 33 branch offices. Geographically, the company operates exclusively within Indonesia, with no international revenue reported. Outlook for FY2024 shows revenue growth of 8.2% year-over-year, driven by expansion of the branch network and product portfolio. The company plans to maintain capital expenditures at -49.1 billion IDR, reflecting a focus on cost control. No recent earnings call transcripts or 10-K filings are available for detailed event analysis. Risk assessment reveals medium liquidity risk due to the current ratio of 1.1 and negative net cash position after subtracting total debt. Dilution risk is classified as low, with no recent share issuance or ATM programs disclosed. The company's leverage position requires monitoring, as long-term debt exceeds equity by 494.4 billion IDR.